This month’s FDA approval of the second TAVR device for valve-in-valve repair in high-risk patients follows the June approval of the third-generation Sapien valve to curb paravalvular leaks.
A study of neurologic outcomes after brain perfusion during total aortic arch replacement finds subclinical damage shows up frequently on brain MRI and neurocognitive testing. What are the implications for practice?
There’s no end in sight to the past decade of progress in transcatheter aortic valve replacement (TAVR). But experts say the coming years may prove to be the decade of TMVR, or transcatheter mitral valve replacement.
Five-year results from the landmark study confirm that transcatheter aortic valve replacement is durable and offers superior survival benefit over standard therapy for inoperable patients with severe aortic stenosis.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The final report from this landmark randomized trial finds no significant difference between transcatheter and surgical aortic valve replacement in mortality or a host of other end points for high-risk surgical patients.
Here’s what you need to know about TAVR, a growing option for patients with severe aortic stenosis who are at high risk or extreme risk for valve replacement surgery
Valve-in-valve TAVR can be a lifesaving treatment for patients with severely degenerated, surgically placed aortic prostheses, who are at extreme risk for open surgical replacement.
Certain topics presented at ACC 2014 are likely to have greater impact on patient care than others. Steven Nissen, MD, chairman of Cardiovascular Medicine at Cleveland Clinic, shares his top five choices.
Results of a US Pivotal Trial secures TAVR s position as the treatment of choice for patients with severe aortic stenosis who cannot undergo surgery and an attractive alternative to standard surgical aortic valve replacement in operable but high-risk patients.